CLE7 homolog Antibody (OTI2A4) [DyLight 405]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-71940V
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot
Label
DyLight 405 (Excitation = 400 nm, Emission = 420 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # OTI2A4
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Full length recombinant protein of human CLE7 homolog (NP_057123) produced in E.coli.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for CLE7 homolog Antibody (OTI2A4) [DyLight 405]
Application
Recommended Usage
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CLE7 homolog
Alternate Names
CGI99, CGI-99, CLE, LCRP369, RLLM1
Gene Symbol
RTRAF
Additional CLE7 homolog Products
Product Documents for CLE7 homolog Antibody (OTI2A4) [DyLight 405]
Product Specific Notices for CLE7 homolog Antibody (OTI2A4) [DyLight 405]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...